Cytophage Technologies Cash Flow Statement

Financials in millions CAD. Fiscal year is January - December.

Millions CAD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2023	FY 2022
Period Ending	Sep '24 Sep 30, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Net Income	-7.91	-4.64	-3.68
Depreciation & Amortization	0.71	0.51	0.36
Stock-Based Compensation	0.3	0.82	0.45
Other Operating Activities	2.65	0.01	-
Change in Accounts Receivable	-0.3	-0.15	-0.11
Change in Accounts Payable	-0.08	0.6	0.06
Change in Other Net Operating Assets	0.04	-0.02	-0.02
Operating Cash Flow	-4.61	-2.86	-2.94
Capital Expenditures	-1.24	-0.16	-0.38
Other Investing Activities	5.39	-2.46	-
Investing Cash Flow	4.15	-2.62	-0.38
Long-Term Debt Issued	-	0.03	-
Long-Term Debt Repaid	-	-0.21	-0.15
Net Debt Issued (Repaid)	-0.35	-0.19	-0.15
Issuance of Common Stock	2.76	0.99	0.88
Other Financing Activities	-0.07	2.45	-
Financing Cash Flow	2.34	3.26	0.73
Net Cash Flow	1.88	-2.21	-2.6
Free Cash Flow	-5.85	-3.02	-3.32
Free Cash Flow Per Share	-0.12	-0.07	-0.08
Cash Interest Paid	0	0	0.02
Levered Free Cash Flow	-	-1.26	-
Unlevered Free Cash Flow	-	-1.24	-
Change in Net Working Capital	-	-0.74	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.